专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06727257B1 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US06727257B1
公开(公告)日：2004-04-27
申请号：US09730458
申请日：2000-12-05
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
IPC分类号： C07D40106
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds of the following formula: wherein A is which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及下式的二氢嘧啶化合物：其中A是人α1C受体的选择性拮抗剂。本发明还涉及这些化合物用于降低眼内压，抑制胆固醇合成，放松下尿路组织，治疗良性前列腺增生，阳ence，心律失常以及用于治疗任何α1C受体拮抗作用的疾病有用本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

2. 发明授权

US06214853B1 Selective NPY (Y5) antagonists (bicyclics) 有权
标题翻译：选择性NPY（Y5）拮抗剂（双环）
公开(公告)号：US06214853B1
公开(公告)日：2001-04-10
申请号：US09343633
申请日：1999-06-30
申请人： Mohammad R. Marzabadi , Wai C. Wong , Yasuchika Yamaguchi , Stewart A. Noble
发明人： Mohammad R. Marzabadi , Wai C. Wong , Yasuchika Yamaguchi , Stewart A. Noble
IPC分类号： A01K31427
CPC分类号： C07D277/60 , C07D277/42 , C07D417/12 , C07D513/04
摘要： This invention is directed to bicyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的双环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

3. 发明授权

US07273880B2 Selective NPY (Y5) antagonists 失效
标题翻译：选择性NPY（Y5）拮抗剂
公开(公告)号：US07273880B2
公开(公告)日：2007-09-25
申请号：US11040328
申请日：2005-01-20
申请人： Mohammad R. Marzabadi , Wai C. Wong , Stewart A. Noble , Yasuchika Yamaguchi
发明人： Mohammad R. Marzabadi , Wai C. Wong , Stewart A. Noble , Yasuchika Yamaguchi
IPC分类号： A61K31/426
CPC分类号： C07D277/60 , C07D277/42 , C07D417/12 , C07D513/04
摘要： This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的双环和三环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了本发明化合物用于制备用于治疗异常的药物组合物的用途，其中所述异常通过降低人Y5受体的活性而减轻。

4. 发明授权

US07071207B2 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity 失效
标题翻译： 1,5,6,7-四氢吡咯并[3,2-c]吡啶衍生物的制备和用途，用于治疗肥胖症
公开(公告)号：US07071207B2
公开(公告)日：2006-07-04
申请号：US10487976
申请日：2002-09-24
申请人： Roger A. Smith , Stephen J. O'Connor , Wai C. Wong , Soongyu Choi , Harold C. Kluender , Jianmei Fan , Zhonghua Zhang , Rico C. Lavoie , Brent L. Podlogar
发明人： Roger A. Smith , Stephen J. O'Connor , Wai C. Wong , Soongyu Choi , Harold C. Kluender , Jianmei Fan , Zhonghua Zhang , Rico C. Lavoie , Brent L. Podlogar
IPC分类号： A61K31/40 , A61K31/395 , A61K31/437 , C07D471/04 , C07D471/14
CPC分类号： C07D471/04
摘要： This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.
摘要翻译：本发明涉及已被发现抑制食欲并引起体重减轻的1,5,6,7-四氢吡咯并[3,2-c]吡啶衍生物。本发明还提供了合成化合物的方法，包含该化合物的药物组合物，以及使用这些组合物诱导体重减轻和治疗肥胖症和肥胖相关疾病的方法。

5. 发明授权

US06777426B2 Imidazole and imidazoline derivatives and uses thereof 失效
标题翻译：咪唑和咪唑啉衍生物及其用途
公开(公告)号：US06777426B2
公开(公告)日：2004-08-17
申请号：US09933106
申请日：2001-08-20
申请人： Wai C. Wong , Yoon T. Jeon , T. G. Murali Dhar , Charles Gluchowski
发明人： Wai C. Wong , Yoon T. Jeon , T. G. Murali Dhar , Charles Gluchowski
IPC分类号： C07D23324
CPC分类号： C07D401/06 , C07D233/50 , C07D401/12 , C07D403/12 , C07D471/04 , C07D491/04 , C07D495/04
摘要： This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及新的咪唑和咪唑啉衍生物，其是用于克隆的人α2肾上腺素能受体的选择性激动剂。本发明还涉及这些化合物用于治疗其中α2受体调节可能有用的任何疾病的用途。本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

6. 发明授权

US06310076B1 Dihydropyridines and new uses thereof 失效
标题翻译：二氢吡啶类及其新用途
公开(公告)号：US06310076B1
公开(公告)日：2001-10-30
申请号：US09588973
申请日：2000-06-07
申请人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
发明人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
IPC分类号： C07D40102
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: wherein Y is —(CH2)n—, where n is 1, 2, 3, 4 or 5; —(CH2)h—O—(CH2)k—, where h and k are independently the same or different and are 2, 3 or 4; —(CH2)h—CH═CH—(CH2)k—; or —(CH2)h—C≡C—(CH2)k—, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH2; wherein R1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R2 and R4 are independently the same or different and are H, or it linear or branched chain alkyl group; wherein R3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R5 and R6 are independently the same or different and are H, OH, Cl, Br, F, NO2, CN, CF3, or NH2, or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group. Other active compounds containing one, two or three rings are also disclosed as well as pharmaceutical compositions prepared therefrom and methods of use in the treatment of BPH, inhibition of cholesterol synthesis, and reduction of intraocular pressure.
摘要翻译：本发明提供一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的具有以下结构的化合物：其中Y为 - （CH 2）n - ，其中n为1,2,3,4 或5; - （CH 2）h -O-（CH 2）k - ，其中h和k独立地相同或不同，为2,3或4; - （CH 2）h -CH = CH-（CH 2）k - ; 或 - （CH 2）h -C = C-（CH 2）k - ，其中h和k独立地相同或不同，为1,2,3或4; 其中Z是O，NH或CH 2; 其中R1是直链或支链烷基，烷氧基烷基或芳基烷基; 其中R2和R4独立地相同或不同，为H，或者是直链或支链烷基; 其中R3是H，直链或支链烷基，烷氧基，烷氧基烷基或酰基; 并且其中R 5和R 6独立地相同或不同，为H，OH，Cl，Br，F，NO 2，CN，CF 3或NH 2，或直链或支链烷基，烷氧基，烷氧基羰基，酰基，烷基亚砜，烷基砜，或一或二烷基氨基。还公开了含有一个，两个或三个环的其它活性化合物以及由其制备的药物组合物和用于治疗BPH，抑制胆固醇合成和降低眼内压的方法。

7. 发明授权

US06268369B1 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US06268369B1
公开(公告)日：2001-07-31
申请号：US08836628
申请日：1997-05-16
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
IPC分类号： C07D4004
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及下式的二氢嘧啶化合物：它们是人α1C受体的选择性拮抗剂。本发明还涉及这些化合物用于降低眼内压，抑制胆固醇合成，放松下尿路组织，治疗良性前列腺增生，阳ence，心律失常以及用于治疗任何α1C受体拮抗作用的疾病有用本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

8. 发明授权

US06248747B1 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US06248747B1
公开(公告)日：2001-06-19
申请号：US09291553
申请日：1999-04-14
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski
IPC分类号： A61K31505
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to the use of dihydropyrimidine compounds, which are selective antagonists for cloned human &agr;1C receptors, for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human &agr;1C receptor is useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-identified compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为克隆的人α1C受体的选择性拮抗剂的二氢嘧啶化合物用于治疗良性前列腺增生症和其它人α1C受体拮抗作用的其它疾病的用途。本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

9. 发明授权

US06245773B1 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US06245773B1
公开(公告)日：2001-06-12
申请号：US08858017
申请日：1997-05-16
申请人： Wai C. Wong , Bharat Lagu , Dhanapalan Nagarathnam , Mohammad R. Marzabadi , Charles Gluchowski
发明人： Wai C. Wong , Bharat Lagu , Dhanapalan Nagarathnam , Mohammad R. Marzabadi , Charles Gluchowski
IPC分类号： A61K31505
CPC分类号： C07D239/22 , A61K31/506 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D451/06 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及下式的二氢嘧啶化合物：它们是人α1A受体的选择性拮抗剂。本发明还涉及这些化合物降低眼内压，抑制胆固醇合成，放松下尿路组织，治疗良性前列腺增生，阳ency，心律失常以及用于治疗任何α1A受体拮抗作用的疾病有用本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

10. 发明授权

US6046331A Imidazolones and their use in treating benign prostatic hyperplasia and other disorders 失效
标题翻译：咪唑啉酮及其在治疗良性前列腺增生等疾病中的应用
公开(公告)号：US6046331A
公开(公告)日：2000-04-04
申请号：US213078
申请日：1998-12-17
申请人： Wai C. Wong , T. G. Murali Dhar , Charles Gluchowski
发明人： Wai C. Wong , T. G. Murali Dhar , Charles Gluchowski
IPC分类号： C07D233/90 , A61K9/06 , A61K9/08 , A61K9/20 , A61K31/4178 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K31/58 , A61K45/00 , A61P3/06 , A61P9/06 , A61P15/00 , A61P15/10 , A61P25/02 , A61P25/06 , A61P27/02 , A61P43/00 , C07D233/70 , C07D401/06 , C07D401/14 , C07D405/14 , C07D491/10 , C07D495/10 , C07D403/00 , A61K31/44 , A61K31/495 , C07D411/00
CPC分类号： C07D401/06 , C07D233/70 , C07D401/14 , C07D405/14 , C07D491/10
摘要： This invention is directed to imidazolones which are selective antagonists for human .alpha..sub.1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the .alpha..sub.1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为人α1a受体的选择性拮抗剂的咪唑啉酮。本发明还涉及这些化合物降低眼内压，抑制胆固醇合成，放松下尿路组织，治疗良性前列腺增生，阳ency，心律失常，交感神经介导的疼痛，偏头痛以及用于治疗任何疾病的用途其中α1a受体的拮抗作用可能是有用的。本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式